secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001171843-25-002849
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva Q1 2025: revenue $3.9B (+5% LC), Non-GAAP EPS $0.52 (+8% YoY); raises FY outlook
--------------------------------------------------------------------------------

- Q1 revenue $3.9B (+5% local currency, +2% reported); GAAP EPS $0.18, Non-GAAP EPS $0.52 (vs $0.48 YoY).
- Key innovative products grew ~39% YoY: AUSTEDO $411M (+39%), AJOVY $139M (+26%), UZEDY $39M.
- FY2025 guidance raised: Non-GAAP EPS $2.45-$2.65 (midpoint +$0.10), Non-GAAP op income $4.3-$4.6B (+$200M at low end).
- Generics grew in all regions (U.S. +5%, Europe +1%, Intl +2% in local currency).
- On track for 30% operating margin by 2027; announces $700M net savings program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000117184325002849/0001171843-25-002849-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000117184325002849/f8k_050725.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-002849

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer